Clinical Study

New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib

Table 3

Risk factors for HHV6 reactivation after autologous SCT*.

HHV-6 positive ( )HHV-6 negative ( )

Age 57 (49–67)53 (35–63)n.s.
Male7 (70%)6 (37.5%)n.s.
Female3 (30%)10 (62.5%)n.s.
Median time from diagnosis to SCT, months (range)8.5 (6–28)7 (5–19)n.s.

Induction regimen*VDTDVDTD
8 (44%)2 (25%)10 (54%)8 (75%)n.s.

Median accumulative steroid dosage, mg (range)880 (640–1600)640 (320–4320)0.038
Pretransplant lymphocyte count (cells/μL)10457300.24

*Calculation represents the proportion of HHV-6 infection in screened patients that were treated with the same induction regimen (VD or TD, resp.).